

Appln. No. 10/553,695
Reply dated August 27, 2008
Reply to Office Action of July 28, 2008

Amendments to the Claims:


This listing of claims will replace all prior versions,
and listings, of claims in the application:

Listing of Claims:

1-26 (Cancelled).


27 (Withdrawn). A cell activator comprising a
glycosphingolipid having a structure represented by the
following formula (1)

formula (1)



wherein R¹ represents the following formula (1-1):

formula (1-1)




Appln. No. 10/553,695
Reply dated August 27, 2008
Reply to Office Action of July 28, 2008

wherein R³ represents alkyl or alkenyl and R⁴ represents alkyl;
and

R² represents hydrogen, or α -galactose, α -glucose,
 α -mannose, α -glucosamine, β -glucosamine or a combination
thereof.

28 (Withdrawn). A cell activator comprising a
glycosphingolipid having a structure represented by the
following formula (3):


formula (3)




wherein R⁵ represents R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷,
R⁵⁸, R⁵⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, or R⁷⁸; and R⁶
represents hydrogen, R⁶², R⁶³, R⁶⁴, or R⁶⁵:

Appl. No. 10/553,695
Reply dated August 27, 2008
Reply to Office Action of July 28, 2008


R⁵¹ :



R⁵² :




R⁵³ :




Appln. No. 10/553,695
Reply dated August 27, 2008
Reply to Office Action of July 28, 2008


R⁵⁴ :




R⁵⁵ :




R⁵⁶ :




R⁵⁷ :



R⁵⁸ :




R⁵⁹ :




Appn. No. 10/553,695
Reply dated August 27, 2008
Reply to Office Action of July 28, 2008


R⁷⁰ :




R⁷¹ :




R⁷² :




R⁷³ :




R⁷⁴ :




R⁷⁵ :




R⁷⁶:




R⁷⁷:




R⁷⁸:




R⁶²:




R⁶⁴:



R⁶³:



R⁶⁵:



29 (Withdrawn). A method of activating NKT cell which comprises administering the cell activator according to claim 27 to a mammal.

30 (Withdrawn). A method of activating NKT cell which comprises administering the cell activator according to claim 28 to a mammal,

31 (Withdrawn). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 27 to a mammal.

32 (Withdrawn). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 28 to a mammal.

33 (Withdrawn). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 27 to a mammal.

34 (Withdrawn). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 28 to a mammal.

35 (Withdrawn). A method of activating dendritic cell which comprises administering the cell activator according to claim 27 to a mammal.

36 (Withdrawn). A method of activating dendritic cell which comprises administering the cell activator to claim 28 to a mammal.

37 (Withdrawn). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 27 to a mammal.

38 (Withdrawn). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (Withdrawn). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 27 to a mammal.

40 (Withdrawn). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (Withdrawn). A method of activating NK cell which comprises administering the cell activator according to claim 27 to a mammal.

42 (Withdrawn). A method of activating NK cell which comprises administering the cell activator according to claim 28 to a mammal.

43 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 27 to a mammal.

44 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 27 to a mammal.

46 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 27 to a mammal.

48 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (Previously Presented). A method of inhibiting viral activity which comprises administering the cell activator according to claim 27 to a mammal.

50 (Previously Presented). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (Withdrawn). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 27 to a mammal.

52 (Withdrawn). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (Withdrawn). A method of accelerating NO production which comprises administering the cell activator according to claim 27 to a mammal.

54 (Withdrawn). A method of accelerating NO production which comprises administering the cell activator according to claim 28 to a mammal.

55 (New). A method of inhibiting viral activity of which comprises administering the cell activator according to claim 28 to a mammal, wherein R⁶ represents hydrogen.

56 (New). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal, wherein R⁵ represents R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, and R⁵⁶.